SCHEMBL22769602

SCHEMBL22769602

O=C(Cc1c(-c2ccccc2)n[nH]c1-c1ccccc1)NO

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KMT2A Q03164 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
ROCK2 O75116 3/20 0.40
ROCK1 Q13464 2/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CCNE2 O96020 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22784055 0.92 MAP2K4 (0.49) KDM4ERAB9ANPC1ALDH1A1GAA
SCHEMBL25143291 0.90 HDAC2 (0.44) KDM4ERAB9ANPC1ALDH1A1GAA
SCHEMBL22784037 0.89 CCNE2 (0.46) KDM4EALDH1A1GAAHPGDKMT2A
SCHEMBL25143437 0.89 MMP3 (0.41) KDM4ERAB9ANPC1ALDH1A1GAA
SCHEMBL22784061 0.87 MAP2K4 (0.46) KDM4EALDH1A1GAAHPGDKMT2A
SCHEMBL22784035 0.87 MAP2K4 (0.53) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL22769603 0.86 HDAC2 (0.47) KDM4ERAB9ANPC1ALDH1A1GAA
SCHEMBL11242632 0.84 KDM4E (0.50) KDM4ERAB9ANPC1ALDH1A1GAA
SCHEMBL25143438 0.84 GRK6 (0.43) MAPK1LMNA
SCHEMBL22774997 0.84 HDAC1 (0.46) KDM4EALDH1A1GAASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388544-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS N.V. (DE) 2025-12-25 US disclosed
EP-3750878-B1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS N V (DE) 2025-05-14 EP disclosed
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases VIVORYON THERAPEUTICS N.V. (DE) 2023-04-20 US disclosed
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases VIVORYON THERAPEUTICS N.V. (DE) 2023-04-20 US disclosed
CN-114585608-A Heteroaromatic inhibitors of astacin protease 维沃永治疗公众有限公司 2022-06-03 CN disclosed
WO-2020249760-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS AG (DE) 2020-12-17 WO disclosed
EP-3750878-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES Vivoryon Therapeutics AG (DE) 2020-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases BMP1, DPEP1, MEP1A KDM4E 2174/4885RAB9A 3956/4885NPC1 980/4885
US-20250388544-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES BMP1, BMPR1A, BMPR1B KDM4E 2946/4885RAB9A 3505/4885NPC1 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.